Metabolites in Glioma Treatment and Diagnosis
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 37
Special Issue Editors
Interests: cancer; tumoral microenvironment; nanomedicine; biotherapeutics; biomarkers
Interests: nanotechnology; nanomedicine; cancer; treatment
Special Issue Information
Dear Colleagues,
In recent decades, significant advances have established new therapeutic options for treating cancer. However, several major challenges remain unresolved. In particular, gliomas are highly aggressive primary brain tumors. Despite the availability of therapeutic options such as surgery, radiotherapy, and alkylating agent chemotherapy, survival rates remain low.
A key issue in these tumors is the presence of metabolic alterations related to the tumor microenvironment, genetic mutations, and other factors. Understanding these alterations is essential, as they may also serve as potential therapeutic targets. The identification, validation, and correlation of these biomolecules represent a promising approach to improving the diagnosis, prognosis, and treatment of this disease.
Therefore, this Special Issue will address topics such as the pathophysiology of glioma in relation to metabolite production, the use of metabolites as diagnostic and prognostic markers, novel therapeutic targets associated with metabolites, and cutting-edge technologies for detecting these biomolecules, as well as their potential therapeutic applications.
Dr. Rosa Angélica Castillo-Rodríguez
Dr. Gabriela Carrasco-Torres
Dr. María Cristina Trejo-Solís
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioma
- metabolites
- treatment
- diagnosis
- prognosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
